Compare Eli Lilly And Co (LLY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs abrdn Physical Palladium Shares ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: Eli Lilly And Co is far larger — about 1774.7× abrdn Physical Palladium Shares ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| LLY | PALL | |
|---|---|---|
Market Cap | $1.04T | $586.03M |
Volume | 3,064,878 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.28K | $37.18 |
52-Week Low | $799.57 | $20.30 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
PALL trades at $20.49, up 0.94% today, but technical indicators signal a bearish trend with moving averages unanimously negative. Recent news highlights palladium's underperformance versus other precious metals, with some analysts viewing current price weakness as a buying opportunity due to supply risks and industrial demand potential. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious; while oversold RSI levels suggest potential for a rebound, bearish momentum dominates. Key risks include commodity price volatility and reliance on industrial demand. Investors should weigh technical weakness against contrarian bullish arguments from recent analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
